The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma
The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma
复制标题
肌钙蛋白相关蛋白 (TROAP) 的上调预示着肝细胞癌的不良预后
DOI：
10.7150/jca.26666
复制
发表时间：
2019-01-01
影响因子：
3.9
通讯作者：
Zhang, Shi-Jun
中科院分区：
文献类型：
--
作者：
Hu, Hao;Xu, Liang;Zhang, Shi-Jun
目的：Trophin-associated protein（TROAP）是一种细胞质蛋白，在胚胎移植和微管调控过程中起重要作用。然而，相关的生存分析和癌症进展分析尚未报道。方法：检测18对配对的肿瘤组织和癌旁组织中TROAP mRNA的表达。采用免疫组化方法检测108例肝细胞癌手术切除标本中TROAP的表达。同时，对TCGA数据库中的数据进行统计学评价。结果如下：在本研究中，我们检测到一个显着增加的TROAP mRNA水平在肿瘤组织与相邻的非肿瘤组织相比。此外，TROAP的上调与血清AFP和GGT升高相关;临床分析中肿瘤数量越大，肿瘤大小、分化程度和癌栓越大。在HCC患者中，原发肿瘤中TROAP表达升高与临床严重程度呈正相关，如总生存率和无病生存率低。此外，单因素和多因素生存分析均证实TROAP表达是HCC患者总生存期和无病生存期的一个有希望的独立危险因素。此外，从TCGA数据库的数据分析得出的结果与以前的结果一致。总之，我们的研究结果表明，TROAP是HCC进展的一种新的关键调节因子，是HCC患者的一种潜在的治疗生物标志物。结论：TROAP的高表达预示着不良的预后，TROAP可能作为一个潜在的生物标志物在肿瘤治疗中的应用。
Purpose: Trophinin-associated protein (TROAP) is a cytoplasmic protein that plays a significant role in the processes of embryo transplantation and microtubule regulation. However, the relevant survival analysis and cancer progression analysis have not yet been reported. Methods: Eighteen matched pairs of tumor and adjacent non-tumor samples were evaluated to detect the TROAP mRNA level. Immunohistochemistry (IHC) was used to evaluate the TROAP expression in 108 hepatocellular carcinoma patients who underwent surgical resection. Meanwhile, data from the TCGA database was statistically evaluated. Results: In the present study, we detected a significant increase in the TROAP mRNA level in tumor tissues when compared with adjacent non-tumor tissues. Moreover, the upregulation of TROAP was associated with increased serum AFP and GGT; the greater the tumor number was, the larger the tumor size, differentiation grade, and cancer embolus in clinical analysis. In HCC patients, elevated TROAP expression in the primary tumor was positively related to clinical severity, such as poor overall survival and disease-free survival. In addition, both univariate and multivariate survival analysis validated that TROAP expression was a promising independent risk factor for overall survival and disease-free survival in HCC patients. Furthermore, the results derived from the analysis of data from the TCGA database were consistent with previous results. Altogether, our results show that TROAP is a novel crucial regulator of HCC progression and is a potential therapeutic biomarker for HCC patients. Conclusions: Elevated TROAP expression predicted a poor prognosis, and TROAP may serve as a potential biomarker for application in oncotherapy.